GlassScriptPhysician profile
Charles Nathaniel Swift
NPI 1609167402
$1,032.86
in general payments reported to CMS, 2019-2025
18 companies · $27.83 in 2025
The $27.83 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $43.65 · 2021: $164 · 2022: $142 · 2023: $166 · 2024: $302 · 2025: $27.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $257.48 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $154.02 | 2019-2024 | |
| Daiichi Sankyo INC. | $110.96 | 2021-2024 | Injectafer |
| Amgen INC. | $109.76 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $67.45 | 2019-2024 | Mounjaro, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $42.83 | 2022-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.97 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $39.81 | 2024 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $32.30 | 2024 | Airsupra |
| Pharmacosmos Therapeutics INC. | $27.83 | 2025 | Monoferric |
| Dexcom, INC. | $27.46 | 2022-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $24.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.14 | 2023 | |
| Astellas Pharma US INC | $16.97 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.87 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.24 | 2021 | |
| Abbvie INC. | $16.12 | 2021 | |
| Sanofi-Aventis U.S. LLC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Swift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.